Redwire Awarded NASA Contract to Expand Pharmaceutical Drug Development in Space for Future Commercialization
Redwire (NYSE: RDW) has secured a NASA contract to conduct four additional pharmaceutical drug investigations on the International Space Station using their Pharmaceutical In-space Laboratory (PIL-BOX). The NASA-funded research aims to manufacture high-value seed crystals that could enhance pharmaceutical manufacturing in space stations.
The company's PIL-BOX platform has already processed 28 units, offering pharmaceutical researchers unique opportunities to grow small-batch crystals of protein-based pharmaceuticals in microgravity. Previous research suggests that space-grown crystals may be more uniform with fewer imperfections, potentially improving drug discovery and development processes. Past investigations have focused on advancing treatments for cardiovascular disease, obesity, and diabetes.
Redwire (NYSE: RDW) ha ottenuto un contratto dalla NASA per condurre quattro ulteriori indagini farmacologiche sulla Stazione Spaziale Internazionale utilizzando il loro Laboratorio Farmaceutico In-Spazio (PIL-BOX). La ricerca finanziata dalla NASA mira a produrre cristalli seme ad alto valore che potrebbero migliorare la produzione farmaceutica nelle stazioni spaziali.
La piattaforma PIL-BOX dell'azienda ha già elaborato 28 unità, offrendo ai ricercatori farmaceutici opportunità uniche di sviluppare cristalli in piccole quantità di farmaci a base proteica in microgravità. Ricerche precedenti suggeriscono che i cristalli cresciuti nello spazio potrebbero essere più uniformi e presentare meno imperfezioni, migliorando potenzialmente i processi di scoperta e sviluppo dei farmaci. Le indagini passate si sono concentrate sull'avanzamento dei trattamenti per malattie cardiovascolari, obesità e diabete.
Redwire (NYSE: RDW) ha conseguido un contrato de la NASA para llevar a cabo cuatro investigaciones farmacéuticas adicionales en la Estación Espacial Internacional utilizando su Laboratorio Farmacéutico en el Espacio (PIL-BOX). La investigación financiada por la NASA tiene como objetivo fabricar cristales semilla de alto valor que podrían mejorar la fabricación farmacéutica en las estaciones espaciales.
La plataforma PIL-BOX de la compañía ya ha procesado 28 unidades, ofreciendo a los investigadores farmacéuticos oportunidades únicas para cultivar cristales en pequeñas cantidades de fármacos a base de proteínas en microgravedad. Investigaciones anteriores sugieren que los cristales cultivados en el espacio pueden ser más uniformes y tener menos imperfecciones, lo que podría mejorar los procesos de descubrimiento y desarrollo de medicamentos. Las investigaciones pasadas se han centrado en avanzar en los tratamientos para enfermedades cardiovasculares, obesidad y diabetes.
레드와이어 (NYSE: RDW)는 NASA와 계약을 체결하여 우주 내 약물 연구소 (PIL-BOX)를 사용하여 국제 우주 정거장에서 네 가지 추가 제약 약물 조사를 수행합니다. NASA 자금을 지원받는 이번 연구는 우주 정거장에서 제약 제조를 향상시킬 수 있는 고부가가치 씨앗 결정체를 제조하는 것을 목표로 합니다.
회사의 PIL-BOX 플랫폼은 이미 28개 유닛을 처리했으며, 제약 연구자들에게 미세 중력에서 단백질 기반 약물의 소량 크리스탈을 성장시킬 수 있는 독특한 기회를 제공합니다. 이전 연구에 따르면, 우주에서 성장한 결정체는 더 균일하고 결함이 적을 수 있어 약물 발견 및 개발 프로세스를 개선할 수 있습니다. 과거 조사는 심혈관 질환, 비만 및 당뇨병 치료의 발전에 중점을 두었습니다.
Redwire (NYSE: RDW) a obtenu un contrat de la NASA pour mener quatre études pharmaceutiques supplémentaires sur la Station spatiale internationale en utilisant leur Laboratoire pharmaceutique en espace (PIL-BOX). La recherche financée par la NASA vise à fabriquer des cristaux semence de haute valeur qui pourraient améliorer la fabrication pharmaceutique dans les stations spatiales.
La plateforme PIL-BOX de l'entreprise a déjà traité 28 unités, offrant aux chercheurs pharmaceutiques des opportunités uniques de faire croître des cristaux en petites quantités de médicaments à base de protéines en microgravité. Des recherches antérieures suggèrent que les cristaux cultivés dans l'espace pourraient être plus uniformes et présenter moins d'imperfections, ce qui pourrait améliorer les processus de découverte et de développement de médicaments. Les enquêtes passées se sont concentrées sur l'avancement des traitements pour les maladies cardiovasculaires, l'obésité et le diabète.
Redwire (NYSE: RDW) hat einen Vertrag mit der NASA gesichert, um vier weitere pharmazeutische Studien an der Internationalen Raumstation unter Verwendung ihres Pharmazeutischen Labors im All (PIL-BOX) durchzuführen. Die von der NASA finanzierte Forschung zielt darauf ab, hochpreisige Saatkristalle herzustellen, die die pharmazeutische Herstellung in Raumstationen verbessern könnten.
Die PIL-BOX-Plattform des Unternehmens hat bereits 28 Einheiten verarbeitet und bietet pharmazeutischen Forschern einzigartige Möglichkeiten, kleine Mengen kristalliner proteinbasierter Arzneimittel in der Mikrogravitation zu züchten. Frühere Forschungen legen nahe, dass im Weltraum gewachsene Kristalle gleichmäßiger und mit weniger Fehlern sein könnten, was potenziell die Prozesse der Arzneimittelentdeckung und -entwicklung verbessert. Frühere Untersuchungen konzentrierten sich auf die Verbesserung von Behandlungen für Herz-Kreislauf-Erkrankungen, Fettleibigkeit und Diabetes.
- Secured new NASA contract for four additional pharmaceutical investigations
- Successfully processed 28 PIL-BOX units to date, demonstrating operational capability
- Expanding presence in pharmaceutical space manufacturing market
- Revenue impact and contract value not disclosed
“NASA has been an instrumental partner and customer as we’ve scaled our pharmaceutical drug manufacturing program significantly over the last year,” said John Vellinger, Redwire’s President of In-Space Industries. “Additional PIL-BOX investigations from NASA and commercial partners will enable Redwire to optimize the infrastructure to launch, test, manufacture, and return high-value space enabled pharmaceutical products and establish a new market in LEO”
With 28 units flown and processed to date, PIL-BOX provides pharmaceutical researchers with novel and flexible services to leverage the microgravity environment to grow small-batch crystals of protein-based pharmaceuticals and other key pharmaceutically relevant molecules. Previous spaceflight investigations indicate that growing crystals in space could yield a more uniform product with fewer imperfections, which can improve the drug discovery and development process. Previous investigations have focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes.
About Redwire
Redwire Corporation (NYSE: RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire’s proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire’s approximately 750 employees working from 17 facilities located throughout
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325785635/en/
Media Contact:
Tere Riley
tere.riley@redwirespace.com
321-831-0134
OR
Investors:
investorrelations@redwirespace.com
904-425-1431
Source: Redwire Corporation
FAQ
What is the purpose of Redwire's new NASA contract for pharmaceutical research in space?
How many PIL-BOX units has Redwire (RDW) processed in space to date?
What medical conditions have been targeted by Redwire's previous space-based pharmaceutical research?
What advantages does space-based crystal growth offer for pharmaceutical development?
